Skip to content

Trial Summary

This study aims to find out how well using Nivolumab on its own before starting standard chemotherapy, or starting treatment with Nivolumab at the same time as standard chemotherapy, helps to reduce tumour size before surgery in patients with previously untreated early stage triple negative breast cancer.

Acronym:

NEO-N BCT

ACTRN/NCT /ethics:

ACTRN12619001308189

Scientific title:

A randomised phase II trial evaluating the efficacy of a nivolumab monotherapy lead in “window” or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancer

Sponsor / Cooperative group:

Breast Cancer Trials

Trial & Patient Characteristics

Cancer TypeBreast
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexAll
Tumour Stream Triple Negative Breast Cancer
Cancer StageEarly\In Situ, Locally Recurrent or Locally Advanced
Anticipated Start Date2020-03-01
Anticipated End Date2022-07-31

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorHannah Adelson
EmailHannah.adelson@sa.gov.au
Phone08 8206 4835
Principal InvestigatorProfessor Chris Karapetis
Recruitment StatusRecruiting